Our ambition is to provide a maximum level of customer convenience.
We implement this goal on several different levels:
We take quality very seriously during all steps of development and manufacturing.
After development, our products are validated according to FDA, EMEA and ICH guidelines and feature a validation report.
Our manufacturing process conforms to GMP/GLP guidelines and complies with the ISO 9001:2015 management system. Products intended for use as in vitro diagnostics (IVD) are also CE marked.
Read more about products validation and quality management at Biomedica.
Founded in 1988, we have over 30 years of experience in the development of immunoassays. This knowledge allows us to guarantee the high quality of our products, to reduce the time needed for developing new products, and to offer great scientific and technical support.
All our products are developed in close collaboration and exchange with scientists and clinicians to ensure we meet our customers’ expectations and needs.
Over the years, Biomedica Immunoassays have become internationally recognized and our customers include numerous top-ranking institutions, well-known CROs, and laboratories in the pharmaceutical industry.
With our contract development service, we make our expertise in immunoassay development available to customers, institutions, and companies requiring a novel test or the professional advancement of an existing test.
Biomedica is part of the AddLife Group, a publicly traded parent company consisting of various subsidiaries in the Life Science and Medical Device fields. AddLife strives to improve people’s lives by being a leading, value creating player in Life Science. As part of this vision, Biomedica develops innovative products for pre-clinical and clinical application. Our products are shipped from Vienna, Austria, in the heart of Europe to all over the world, either directly or via our local distributors. Our development and production facilities are in Bratislava, Slovakia, only an hour’s drive away from Vienna.
Our staff in Bratislava is also in charge of all ELISA service measurements allowing tight coordination of production and measurements.
At Biomedica, we embrace diversity and are proud to have an above-average proportion of female scientists and staff. We are an enthusiastic and compassionate team that values each person´s talents and personality. Our culture of respect and reliability not only makes Biomedica a great place to work, it is also the foundation of the close relationship with our customers.
We ensure worldwide availability and customer support by cooperating with selected local distributors on all continents.
Our long-term partner in assay development is The Antibody Lab GmbH, a private biotechnology company based in Vienna. Biomedica and The Antibody Lab work closely together to select, develop, and establish new biomarker assays. By attending conferences and meetings together, we maintain a close relationship with our customers and keep them up to date with the latest discoveries in life science and medical research.
We are proud to be partnering with and act as a global distributor of:
TAmiRNA, a Vienna-based startup specializing in the detection of microRNA biomarkers. Using the osteomiR™, thrombomiR™, and toxomiR™ kits, verified microRNA biomarkers are detected in serum and plasma samples to assess fracture risk, platelet function, and toxicity, respectively.
Fianostics, an Austrian based startup developing and producing patented FluoBolt™ - high sensitivity fluorescence immunoassays for analytes which are hard to detect by conventional ELISA technology. Currently available: FluoBolt™ Noggin FIA, FluoBolt™ Periostin FIA, and FluoBolt™ Asporin FIA.
Finally, we are the exclusive partner of Glycotechnica Ltd, a Japanese biotechnology company, in Europe. Using lectin-based microarrays (LecChip™), their proprietary innovative technology enables quick and accurate glycan profiling for any complex glycans, even for mixtures.